Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy

Interleukin-2 (IL-2) is a cytokine with pleiotropic effects on the immune system. Systemic IL-2 treatment has produced durable responses in melanoma and renal cancer patients, but unfortunately this is effective only in a fraction of patients. Moreover, IL-2 treatment also engenders serious side effects, which limit its clinical utility. It is now appreciated that IL-2 not only stimulates NK and effector T cells but also has a critical role in the generation and maintenance of regulatory T cells, which act to dampen immune responses. Thus, successful immunotherapy of cancers using IL-2 has to address two fundamentally important issues: (1) how to limit side effects yet be active where it is needed, and (2) how to preferentially activate effector T cells while limiting the stimulation of Tregs. Strategies are now being developed to address these critical obstacles that may lead to a renaissance of IL-2 therapy.

[1]  D. Neri,et al.  Immunocytokines: a review of molecules in clinical development for cancer therapy , 2013, Clinical pharmacology : advances and applications.

[2]  J. Wolchok,et al.  Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Ana R. Pacios,et al.  Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2 , 2013, The Journal of Immunology.

[4]  E. Ranheim,et al.  Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival , 2013, Cancer Immunology, Immunotherapy.

[5]  J. Ritz,et al.  Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease , 2013, Science Translational Medicine.

[6]  Yan Zheng,et al.  Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. , 2013, Current opinion in immunology.

[7]  S. Gerber,et al.  Local expression of interleukin‐2 by B16 melanoma cells results in decreased tumour growth and long‐term tumour dormancy , 2013, Immunology.

[8]  W. Leonard,et al.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. , 2013, Immunity.

[9]  E. Shevach.  Application of IL-2 therapy to target T regulatory cell function. , 2012, Trends in immunology.

[10]  J. Taube,et al.  Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.

[11]  T. Malek,et al.  Transient Enhanced IL-2R Signaling Early during Priming Rapidly Amplifies Development of Functional CD8+ T Effector-Memory Cells , 2012, The Journal of Immunology.

[12]  E. Ranheim,et al.  Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention , 2012, The Journal of Immunology.

[13]  E. Bonifacio.  Immunotherapy in Type 1 Diabetes: A Shorter but More Winding Road? , 2012, Diabetes.

[14]  J. Bluestone,et al.  Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function , 2012, Diabetes.

[15]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[16]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[17]  KyungMann Kim,et al.  Phase II trial of hu14.18-IL2 for patients with metastatic melanoma , 2012, Cancer Immunology, Immunotherapy.

[18]  Amy K. Erbe,et al.  Increasing the Clinical Efficacy of NK and Antibody-Mediated Cancer Immunotherapy: Potential Predictors of Successful Clinical Outcome Based on Observations in High-Risk Neuroblastoma , 2012, Front. Pharmacol..

[19]  J. Sprent,et al.  Selectively expanding subsets of T cells in mice by injection of interleukin-2/antibody complexes: implications for transplantation tolerance. , 2012, Transplantation proceedings.

[20]  T. Strom,et al.  Prolonged Survival of Allogeneic Islets in Cynomolgus Monkeys After Short‐Term Triple Therapy , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  T. Strom,et al.  Effects of an agonist interleukin-2/Fc fusion protein, a mutant antagonist interleukin-15/Fc fusion protein, and sirolimus on cardiac allograft survival in non-human primates. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[22]  A. Rudensky,et al.  Regulatory T cells: mechanisms of differentiation and function. , 2012, Annual review of immunology.

[23]  Jonathan S. Paw,et al.  Treating Human Autoimmunity: Current Practice and Future Prospects , 2012, Science Translational Medicine.

[24]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[25]  S. Rosenberg,et al.  CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.

[26]  Mark A. Atkinson,et al.  Central Role for Interleukin-2 in Type 1 Diabetes , 2011, Diabetes.

[27]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[28]  F. Carrat,et al.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. , 2011, The New England journal of medicine.

[29]  J. Bluestone.  The yin and yang of interleukin-2-mediated immunotherapy. , 2011, The New England journal of medicine.

[30]  M. Patankar,et al.  Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface , 2011, Cancer Immunology, Immunotherapy.

[31]  F. Marincola,et al.  gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.

[32]  J. Sprent,et al.  Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells , 2011, Nature Immunology.

[33]  J. Frelinger,et al.  Development of an attenuated interleukin‐2 fusion protein that can be activated by tumour‐expressed proteases , 2011, Immunology.

[34]  S. O. Mueller,et al.  A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity , 2011, Clinical Cancer Research.

[35]  S. Jameson,et al.  IL-2 Complex Treatment Can Protect Naive Mice from Bacterial and Viral Infection , 2010, The Journal of Immunology.

[36]  J. Maris,et al.  Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. , 2010, Cancer research.

[37]  J. Maris,et al.  Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  T. Malek,et al.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity. , 2010, Immunity.

[39]  G. Pantaleo,et al.  Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells , 2010, Proceedings of the National Academy of Sciences.

[40]  Dan R. Littman,et al.  Th17 and Regulatory T Cells in Mediating and Restraining Inflammation , 2010, Cell.

[41]  W. Haining,et al.  Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. , 2010, Immunity.

[42]  M. Bevan,et al.  Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. , 2010, Immunity.

[43]  J. Sprent,et al.  IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25 , 2010, Proceedings of the National Academy of Sciences.

[44]  J. Maranchie,et al.  Pharmacologic Administration of Interleukin‐2 , 2009, Annals of the New York Academy of Sciences.

[45]  T. Mrkvan,et al.  In Vivo Expansion of Activated Naive CD8+ T Cells and NK Cells Driven by Complexes of IL-2 and Anti-IL-2 Monoclonal Antibody As Novel Approach of Cancer Immunotherapy1 , 2009, The Journal of Immunology.

[46]  M. Atkins,et al.  Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma , 2009, Journal of Translational Medicine.

[47]  Mohamed A. Shaker,et al.  Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. , 2009, Journal of pharmaceutical sciences.

[48]  E. Shevach.  Mechanisms of foxp3+ T regulatory cell-mediated suppression. , 2009, Immunity.

[49]  P. Gregersen,et al.  Structural biology of shared cytokine receptors. , 2009, Annual review of immunology.

[50]  A. Livingstone,et al.  Cutting Edge: CD4+ T Cell-Derived IL-2 Is Essential for Help-Dependent Primary CD8+ T Cell Responses1 , 2008, The Journal of Immunology.

[51]  L. Sherman,et al.  Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy , 2008, Proceedings of the National Academy of Sciences.

[52]  T. Hirano,et al.  Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation. , 2008, International immunology.

[53]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[54]  J. Bluestone,et al.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.

[55]  D. Sojka,et al.  Mechanisms of regulatory T‐cell suppression – a diverse arsenal for a moving target , 2008, Immunology.

[56]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[57]  M. Bevan,et al.  Naive CD8+ T cells differentiate into protective memory-like cells after IL-2–anti–IL-2 complex treatment in vivo , 2007, The Journal of experimental medicine.

[58]  M. Atkins,et al.  Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer , 2007, Clinical Cancer Research.

[59]  T. Hirano,et al.  IL-2 In Vivo Activities and Antitumor Efficacy Enhanced by an Anti-IL-2 mAb1 , 2006, The Journal of Immunology.

[60]  Michael Y. Gerner,et al.  Signals required for programming effector and memory development by CD8+ T cells , 2006, Immunological reviews.

[61]  Clare Baecher-Allan,et al.  Immune regulation in tumor-bearing hosts. , 2006, Current opinion in immunology.

[62]  J. Sprent,et al.  Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes , 2006, Science.

[63]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[64]  David Schrama,et al.  Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[65]  D. Lauffenburger,et al.  High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. , 2005, Biochemistry.

[66]  P. Wei,et al.  Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice , 2005, Cancer Immunology, Immunotherapy.

[67]  R. Ralston,et al.  Combination Nonviral Interleukin‐2 Gene Immunotherapy For Head and Neck Cancer: From Bench Top to Bedside , 2005, The Laryngoscope.

[68]  S. Morrison,et al.  Antibody-cytokine fusion proteins: innovative weapons in the war against cancer , 2004, Clinical and Experimental Medicine.

[69]  D. Lauffenburger,et al.  Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor α-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect , 2004 .

[70]  S. Gillies,et al.  Enhanced Activity of Hu14.18-IL2 Immunocytokine against Murine NXS2 Neuroblastoma when Combined with Interleukin 2 Therapy , 2004, Clinical Cancer Research.

[71]  F. Marincola,et al.  Forecasting the cytokine storm following systemic interleukin (IL)-2 administration , 2004, Journal of Translational Medicine.

[72]  T. Olencki,et al.  Preliminary pharmacokinetic evaluation of Albuleukin; an interleukin-2 human serum albumin fusion protein, in solid tumor patients , 2004 .

[73]  D. Lauffenburger,et al.  Interleukin‐2 mutants with enhanced α‐receptor subunit binding affinity , 2003 .

[74]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Of Interest , 2002, Quaternary Research.

[76]  M. Choti,et al.  Controlled Local Delivery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain Tumors and Liver Tumors , 2001, Pharmaceutical Research.

[77]  Christopher A. Carter,et al.  A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo , 2000, Nature Biotechnology.

[78]  M. Sabel,et al.  In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. , 2000, Cancer research.

[79]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  J. Marks,et al.  Redirecting effector T cells through their IL-2 receptors. , 1999, Journal of immunology.

[81]  S. Steinberg,et al.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. , 1998, Annals of surgery.

[82]  W. Muller,et al.  Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[83]  A. McAdam,et al.  Synergistic effects of co‐expression of the Th1 cytokines il‐2 and IFNγ on generation of murine tumor‐reactive cytotoxic cells , 1995, International Journal of Cancer.

[84]  L. Karavodin,et al.  An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. , 1994, Immunopharmacology.

[85]  P. Anderson,et al.  Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2 , 1994, Clinical pharmacokinetics.

[86]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[87]  F. Finkelman,et al.  Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. , 1993, Journal of immunology.

[88]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[89]  P W Mansell,et al.  Pharmacokinetics of recombinant interleukin 2 in humans. , 1990, Cancer research.

[90]  H. Ohnishi,et al.  Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. , 1990, Cancer research.

[91]  Kendall A. Smith,et al.  Interleukin-2: inception, impact, and implications. , 1988, Science.

[92]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. , 1985, Journal of immunology.

[93]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. , 1985, Journal of immunology.

[94]  S. Rosenberg,et al.  The fate of interleukin-2 after in vivo administration. , 1983, Journal of immunology.

[95]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[96]  K. Leon,et al.  Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping. , 2013, Immunobiology.

[97]  D. Lauffenburger,et al.  Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. , 2004, Molecular pharmacology.

[98]  T. Strom,et al.  ISLET TRANSPLANTATION : ADVANCES AND IMMUNOLOGICAL CHALLENGES , 2004 .

[99]  D. Lauffenburger,et al.  Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. , 2003, Protein engineering.

[100]  R. Siegel,et al.  Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. , 1999, Annual review of immunology.